M. Mercken

发表

Detection of tau proteins in normal and Alzheimer's disease cerebrospinal fluid with a sensitive sandwich enzyme-linked immunosorbent assay.

M. Vandermeeren, M. Mercken, E. Vanmechelen, 1993, Journal of neurochemistry.

A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease.

P. S. St George-Hyslop, D. Westaway, P. Fraser, 2000, Nature.

The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics

B. Strooper, M. Mercken, E. Karran, 2011, Nature Reviews Drug Discovery.

The Neural Cell Adhesion Molecules L1 and CHL1 Are Cleaved by BACE1 Protease in Vivo*

B. de Strooper, Mathias Laga, M. Mercken, 2012, The Journal of Biological Chemistry.

Increased expression of BIN1 mediates Alzheimer genetic risk by modulating tau pathology

M. Owen, Y. Kamatani, G. Drewes, 2013, Molecular Psychiatry.

Reduction of Abeta levels in the Sprague Dawley rat after oral administration of the functional gamma-secretase inhibitor, DAPT: a novel non-transgenic model for Abeta production inhibitors.

T. Meert, M. Vandermeeren, M. Mercken, 2006, Current pharmaceutical design.

Reduction of Aβ Levels in the Sprague Dawley Rat After Oral Administration of the Functional g-Secretase Inhibitor, DAPT: A Novel Non- Transgenic Model for Aβ Production Inhibitors

T. Meert, M. Vandermeeren, M. Mercken, 2006 .

Alzheimer's disease-related overexpression of the cation-dependent mannose 6-phosphate receptor increases Abeta secretion: role for altered lysosomal hydrolase distribution in beta-amyloidogenesis.

J. Rohrer, P. Mehta, M. Mercken, 2002, The Journal of biological chemistry.

Virus-Based Expression Systems Facilitate Rapid Target In Vivo Functionality Validation and High-Throughput Screening

Zina Itkin, Mary Jo Wildey, Sergey E. Ilyin, 2003, Journal of biomolecular screening.

Extracellular interface between APP and Nicastrin regulates Aβ length and response to γ‐secretase modulators

M. Zacharias, M. Mercken, Sam Lismont, 2019, The EMBO journal.

Glycogen Synthase Kinase-3β Phosphorylates Protein Tau and Rescues the Axonopathy in the Central Nervous System of Human Four-repeat Tau Transgenic Mice*

M. Mercken, K. Bruynseels, F. van Leuven, 2000, The Journal of Biological Chemistry.

Differential sensitivity to proteolysis by brain calpain of adult human tau, fetal human tau and PHF‐tau

M. Mercken, R. Nixon, F. Grynspan, 1995, FEBS letters.

Prominent Cerebral Amyloid Angiopathy in Transgenic Mice Overexpressing the London Mutant of Human APP in Neurons

H. Vanderstichele, I. Tesseur, R. Sciot, 2000 .

Characterization of tau phosphorylation in glycogen synthase kinase-3beta and cyclin dependent kinase-5 activator (p23) transfected cells.

K. Imahori, M. Mercken, A. Takashima, 1998, Biochimica et biophysica acta.

Calpain Activity Regulates the Cell Surface Distribution of Amyloid Precursor Protein

M. Mercken, S. Schmidt, P. Mathews, 2002, The Journal of Biological Chemistry.

[32P]orthophosphate and [35S]methionine label separate pools of neurofilaments with markedly different axonal transport kinetics in mouse retinal ganglion cells in vivo

M. Mercken, R. Nixon, S. Lewis, 1994, Neurochemical Research.

A canine model to evaluate efficacy and safety of γ-secretase inhibitors and modulators.

M. Mercken, F. De Ridder, L. Dillen, 2012, Journal of Alzheimer's disease : JAD.

BACE1 Dynamics Upon Inhibition with a BACE Inhibitor and Correlation to Downstream Alzheimer’s Disease Markers in Elderly Healthy Participants

L. Shaw, B. de Strooper, S. Engelborghs, 2017, Journal of Alzheimer's disease : JAD.

Aβ vaccination of a genetic model of Alzheimer's disease

D. Westaway, P. Fraser, P. George-Hyslop, 2003 .

Tricyclic 3,4-dihydropyrimidine-2-thione derivatives as potent TRPA1 antagonists.

M. Mercken, B. Brône, Didier Berthelot, 2012, Bioorganic & medicinal chemistry letters.

Detection of Proteins in Normal and Alzheimer's Disease Cerebrospinal Fluid with a Sensitive Sandwich Enzyme‐Linked Immunosorbent Assay

Jan Six, Eugeen Vanmechelen, M. Vandermeeren, 1993 .

Impact of frequent cerebrospinal fluid sampling on Aβ levels: systematic approach to elucidate influencing factors

L. Shaw, S. Engelborghs, J. Streffer, 2016, Alzheimer's Research & Therapy.

Decreased Deposition of Beta-Amyloid 1-38 and Increased Deposition of Beta-Amyloid 1-42 in Brain Tissue of Presenilin-1 E280A Familial Alzheimer’s Disease Patients

J. Streffer, M. Mercken, F. Lopera, 2020, Frontiers in Aging Neuroscience.

Dual Roles of Proteasome in the Metabolism of Presenilin 1

Hiroshi Takahashi, M. Mercken, A. Takashima, 1999, Journal of neurochemistry.

Restricted Location of PSEN2/γ-Secretase Determines Substrate Specificity and Generates an Intracellular Aβ Pool

J. Bonifacino, B. Strooper, M. Bollen, 2016, Cell.

Nonfibrillar diffuse amyloid deposition due to a γ 42-secretase site mutation points to an essential role for N-truncated A β 42 in Alzheimer ’ s disease

H. Vanderstichele, B. Strooper, C. Broeckhoven, 2000 .

Nonfibrillar diffuse amyloid deposition due to a gamma(42)-secretase site mutation points to an essential role for N-truncated A beta(42) in Alzheimer's disease.

H. Vanderstichele, B. Strooper, B. de Strooper, 2000, Human molecular genetics.

Normal brain development in PS1 hypomorphic mice with markedly reduced γ-secretase cleavage of βAPP

R. Rozmahel, D. Westaway, P. George-Hyslop, 2002, Neurobiology of Aging.

Design and synthesis of a novel series of bicyclic heterocycles as potent γ-secretase modulators.

G. Macdonald, G. Tresadern, M. Mercken, 2012, Journal of medicinal chemistry.

Different effects of Alzheimer-associated mutations of presenilin 1 on its processing

Hiroshi Takahashi, M. Mercken, A. Takashima, 1997, Neuroscience Letters.

Upregulation of B-50/GAP-43 in Schwann cells at denervated motor endplates and in motoneurons after rat facial nerve crush.

M. Mercken, W. Gispen, J. Verhaagen, 1993, Restorative neurology and neuroscience.

Development and Validation of a High Sensitivity Assay for Measuring p217 + tau in Cerebrospinal Fluid

M. Mercken, W. Galpern, H. Kolb, 2020, Journal of Alzheimer's disease : JAD.

Impaired proteolytic processing of Presenilin-1 in chromosome 14-linked familial Alzheimer's disease patient lymphocytes

Hiroshi Takahashi, M. Mercken, A. Takashima, 1999, Neuroscience Letters.

Cloning of cDNA and expression of the gene encoding rat presenilin-2.

K. Imahori, M. Mercken, A. Takashima, 1997, Gene.

Characterization of human presenilin 1 using N‐terminal specific monoclonal antibodies: Evidence that Alzheimer mutations affect proteolytic processing

K. Imahori, Hiroshi Takahashi, M. Mercken, 1996, FEBS letters.

Molecular cloning and expression of the rat homologue of presenilin-1

K. Imahori, Hiroshi Takahashi, M. Mercken, 1996, Neuroscience Letters.

CSF p-tau increase in response to Aβ-type and Danish-type cerebral amyloidosis and in the absence of neurofibrillary tangles

M. Mercken, M. Jucker, S. Kaeser, 2021, Acta Neuropathologica.

Development and validation of a high‐sensitivity assay for measuring p217+tau in plasma

M. Mercken, H. Kolb, G. Triana-Baltzer, 2021, Alzheimer's & dementia.

Comparison of two different methods for measurement of amyloid-β peptides in cerebrospinal fluid after BACE1 inhibition in a dog model.

M. Mercken, T. Jacobs, L. Dillen, 2013, Journal of Alzheimer's disease : JAD.

Alzheimer’s-causing mutations shift Aβ length by destabilizing γ-secretase-Aβn interactions

Nick C Fox, B. Strooper, C. Hopf, 2021, Cell.

No endogenous A beta production in presenilin-deficient fibroblasts.

B. de Strooper, M. Mercken, W. Annaert, 2002, Nature cell biology.

Characterization of Aβ11-40/42 peptide deposition in Alzheimer’s disease and young Down’s syndrome brains: implication of N-terminally truncated Aβ species in the pathogenesis of Alzheimer’s disease

J. Trojanowski, V. Lee, M. Mercken, 2006, Acta Neuropathologica.

Prominent Cerebral Amyloid Angiopathy in Transgenic Mice

H. Vanderstichele, I. Tesseur, R. Sciot, 2000 .

Macroautophagy—a novel (cid:1) -amyloid peptide-generating pathway activated in Alzheimer’s disease

L. Tjernberg, M. Mercken, S. Schmidt, 2005 .

No endogenous Aβ production in presenilin-deficient fibroblasts

B. Strooper, M. Mercken, W. Annaert, 2002, Nature Cell Biology.

Destabilized γ-Secretase-Aβn interactions cause Alzheimer’s disease, implications for drug discovery

Nick C Fox, B. Strooper, C. Hopf, 2017 .

Neurite sprouting and cytoskeletal pathology in Alzheimer's disease: a comparative study with monoclonal antibodies to growth associated protein B-50 and paired helical filaments

M. Vandermeeren, M. Mercken, J. Six, 1992 .

Profiling the dynamics of CSF and plasma Aβ reduction after treatment with JNJ-54861911, a potent oral BACE inhibitor

Vikash K. Sinha, E. Liu, L. Shaw, 2016, Alzheimer's & dementia.

Featured Article Profiling the dynamics of CSF and plasma Ab reduction after treatment with JNJ-54861911, a potent oral BACE inhibitor

Vikash K. Sinha, E. Liu, L. Shaw, 2016 .

Specific monoclonal antibodies against normal microtubule-associated protein-2 (MAP2) epitopes present in Alzheimer pathological structures do not recognize paired helical filaments

M. Vandermeeren, M. Mercken, J. Six, 2004, Acta Neuropathologica.

Aβ localization in abnormal endosomes: association with earliest Aβ elevations in AD and Down syndrome

J. Buxbaum, V. Haroutunian, P. Mehta, 2004, Neurobiology of Aging.

Comparison of size distribution and (Pro249-Ser258) epitope exposure in in vitro and in vivo derived Tau fibrils

M. Mercken, L. Schoofs, L. Temmerman, 2020, BMC molecular and cell biology.

Monoclonal Antibody NM2 Recognizes the Protein Kinase C Phosphorylation Site in B‐50 (GAP‐43) and in Neurogranin (BICKS)

M. Mercken, W. Gispen, A. Oestreicher, 1994, Journal of neurochemistry.

Immunocytochemical detection of the growth-associated protein B-50 by newly characterized monoclonal antibodies in human brain and muscle.

M. Vandermeeren, M. Mercken, A. Oestreicher, 1992, Journal of neurobiology.

N‐Terminal‐Specific Anti‐B‐50 (GAP‐43) Antibodies Inhibit Ca2+‐Induced Noradrenaline Release, B‐50 Phosphorylation and Dephosphorylation, and Calmodulin Binding

M. Mercken, F. Boomsma, W. Gispen, 1995, Journal of neurochemistry.

Affinity Purification of Human τ Proteins and the Construction of a Sensitive Sandwich Enzyme‐Linked Immunosorbent Assay for Human τ Detection

M. Vandermeeren, M. Mercken, J. Six, 1992, Journal of neurochemistry.

Isolation of IgG1-secreting switch variants from IgM hybridomas produced after in vitro immunization.

M. Vandermeeren, M. Mercken, A. Van de Voorde, 1991, Journal of immunological methods.

Extracellular amyloid formation and associated pathology in neural grafts

M. Staufenbiel, M. Mercken, M. Meyer-Luehmann, 2003, Nature Neuroscience.

Discovery and Functional Characterization of hPT3, a Humanized Anti-Phospho Tau Selective Monoclonal Antibody.

J. Trojanowski, M. Vandermeeren, M. Mercken, 2020, Journal of Alzheimer's disease : JAD.

2-Amino-3,4-dihydroquinazolines as inhibitors of BACE-1 (beta-site APP cleaving enzyme): Use of structure based design to convert a micromolar hit into a nanomolar lead.

Junya Qu, Allen B Reitz, Brett A Tounge, 2007, Journal of medicinal chemistry.

Analogues of morphanthridine and the tear gas dibenz[b,f][1,4]oxazepine (CR) as extremely potent activators of the human transient receptor potential ankyrin 1 (TRPA1) channel.

M. Mercken, B. Brône, M. Zaja, 2010, Journal of medicinal chemistry.

Tear gasses CN, CR, and CS are potent activators of the human TRPA1 receptor.

Theo Meert, Roger Marrannes, T. Meert, 2008, Toxicology and applied pharmacology.

Acute function of secreted amyloid precursor protein fragment APPsα in synaptic plasticity

A. Draguhn, M. Mercken, L. Slomianka, 2014, Acta Neuropathologica.

Design and synthesis of a novel series of cyanoindole derivatives as potent γ-secretase modulators.

G. Macdonald, M. Mercken, S. Samanta, 2019, Bioorganic & medicinal chemistry letters.

Anilinotriazoles as potent gamma secretase modulators.

G. Macdonald, G. Tresadern, M. Mercken, 2014, Bioorganic & medicinal chemistry letters.

Prominent axonopathy in the brain and spinal cord of transgenic mice overexpressing four-repeat human tau protein.

H. Geerts, R. Sciot, M. Mercken, 1999, The American journal of pathology.

Macroautophagy—a novel β-amyloid peptide-generating pathway activated in Alzheimer's disease

L. Tjernberg, M. Mercken, S. Schmidt, 2005, The Journal of cell biology.

Alzheimer's Disease-related Overexpression of the Cation-dependent Mannose 6-Phosphate Receptor Increases Aβ Secretion

J. Rohrer, P. Mehta, M. Mercken, 2002, The Journal of Biological Chemistry.

Neuronal Deficiency of Presenilin 1 Inhibits Amyloid Plaque Formation and Corrects Hippocampal Long-Term Potentiation But Not a Cognitive Defect of Amyloid Precursor Protein [V717I] Transgenic Mice

E. Godaux, M. Mercken, L. Serneels, 2002, The Journal of Neuroscience.

Intracerebral injection of preformed synthetic tau fibrils initiates widespread tauopathy and neuronal loss in the brains of tau transgenic mice

J. Trojanowski, V. Lee, M. Mercken, 2015, Neurobiology of Disease.

Macrocyclic BACE inhibitors: Optimization of a micromolar hit to nanomolar leads.

M. Vandermeeren, M. Mercken, C. Ho, 2010, Bioorganic & medicinal chemistry letters.

Acute rise in the concentration of free cytoplasmic calcium leads to dephosphorylation of the microtubule-associated protein tau

M. Mercken, R. Nixon, M. Beermann, 1997, Brain Research.

The switch of tau protein to an Alzheimer‐like state includes the phosphorylation of two serine‐proline motifs upstream of the microtubule binding region.

E. Mandelkow, E. Mandelkow, M. Mercken, 1992, The EMBO journal.

Neonatal neuronal overexpression of glycogen synthase kinase-3β reduces brain size in transgenic mice

B. Hyman, M. Verhoye, A. Linden, 2002, Neuroscience.

Epitope mapping and structural basis for the recognition of phosphorylated tau by the anti‐tau antibody AT8

G. Gilliland, M. Vandermeeren, M. Mercken, 2016, Proteins.

Aβ peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease

Ralph A. Nixon, Paul M. Mathews, Patrick Horne, 2000, Nature.

Amyloid precursor protein mutation E682K at the alternative β-secretase cleavage β′-site increases Aβ generation†

B. de Strooper, K. Sleegers, C. van Broeckhoven, 2011, EMBO molecular medicine.

Presenilin 1 associates with glycogen synthase kinase-3beta and its substrate tau.

M. Mercken, A. Takashima, T. Kohno, 1998, Proceedings of the National Academy of Sciences of the United States of America.

Endogenous amyloid‐β is necessary for hippocampal synaptic plasticity and memory

A. Palmeri, O. Arancio, M. Mercken, 2011, Annals of neurology.

Demonstration of a novel neurofilament associated antigen with the neurofibrillary pathology of Alzheimer and related diseases

M. Tabaton, M. Vandermeeren, M. Mercken, 1991, Brain Research.

Bexarotene treatment does not clear β-Amyloid in an AD mouse model and Beagle dogs

R. D'Hooge, B. de Strooper, I. Tesseur, 2013, Molecular Neurodegeneration.

Cerebrospinal fluid p-tau217 performs better than p-tau181 as a biomarker of Alzheimer’s disease

D. Airey, O. Hansson, M. Mercken, 2020 .

A Cholesterol-Lowering Drug Reduces β-Amyloid Pathology in a Transgenic Mouse Model of Alzheimer's Disease

M. Mercken, S. Schmidt, J. Lafrancois, 2001, Neurobiology of Disease.

Passive immunotherapy with a novel antibody against 3pE-modified Aβ demonstrates potential for enhanced efficacy and favorable safety in combination with BACE inhibitor treatment in plaque-depositing mice

M. Vandermeeren, M. Mercken, D. Moechars, 2021, Neurobiology of Disease.

BACE1 Inhibition Induces a Specific Cerebrospinal Fluid β-Amyloid Pattern That Identifies Drug Effects in the Central Nervous System

K. Blennow, M. Mercken, H. Zetterberg, 2012, PloS one.

Alzheimer’s-Causing Mutations Shift Aβ Length by Destabilizing γ-Secretase-Aβn Interactions

N. Fox, B. Strooper, C. Hopf, 2017, Cell.

Exposure of rat hippocampal neurons to amyloid β peptide (25–35) induces the inactivation of phosphatidyl inositol-3 kinase and the activation of tau protein kinase I/glycogen synthase kinase-3β

K. Imahori, M. Mercken, A. Takashima, 1996, Neuroscience Letters.

Lack of neprilysin suffices to generate murine amyloid‐like deposits in the brain and behavioral deficit in vivo

H. Lipp, R. Nitsch, M. Mercken, 2006, Journal of neuroscience research.

Anti-Tau Monoclonal Antibodies Derived from Soluble and Filamentous Tau Show Diverse Functional Properties in vitro and in vivo.

M. Vandermeeren, M. Mercken, Rupesh K. Nanjunda, 2018, Journal of Alzheimer's disease : JAD.

Presenilin Redistribution Associated with Aberrant Cholesterol Transport Enhances β-Amyloid Production In Vivo

M. Mercken, Y. Matsuoka, P. Mathews, 2003, The Journal of Neuroscience.

APLP1 as a cerebrospinal fluid biomarker for γ-secretase modulator treatment

K. Blennow, M. Mercken, H. Zetterberg, 2015, Alzheimer's Research & Therapy.

Diagnostic Accuracy of Cerebrospinal Fluid Amyloid-β Isoforms for Early and Differential Dementia Diagnosis.

H. Struyfs, K. Sleegers, C. van Broeckhoven, 2015, Journal of Alzheimer's disease : JAD.

Central sensitization of nociceptive pathways demonstrated by robot-controlled pinprick-evoked brain potentials

A. Mouraux, M. Mercken, E. V. D. Broeke, 2020, Clinical Neurophysiology.

Method for the determination of the levels of beta-amyloid peptide in the CSF sampled from freely moving rats.

T. Meert, M. Mercken, C. Mackie, 2005, Journal of pharmacological and toxicological methods.

Impact of cerebrospinal fluid matrix on the detection of Alzheimer's disease with Aβ42 and influence of disease on the total‐Aβ42/Aβ40 ratio

K. Blennow, J. Streffer, M. Mercken, 2015, Journal of neurochemistry.

The Alzheimer’s Association external quality control program for cerebrospinal fluid biomarkers

Giovanni B. Frisoni, José Luis Molinuevo, Aase Handberg, 2011, Alzheimer's & Dementia.

Monoclonal antibodies with selective specificity for Alzheimer Tau are directed against phosphatase-sensitive epitopes

M. Vandermeeren, M. Mercken, J. Six, 2004, Acta Neuropathologica.

Characterization of amyloid β peptides from brain extracts of transgenic mice overexpressing the London mutant of human amyloid precursor protein

Lieve Dillen, M. Mercken, D. Moechars, 2003 .

Characterization of amyloid beta peptides from brain extracts of transgenic mice overexpressing the London mutant of human amyloid precursor protein.

M. Mercken, D. Moechars, L. Dillen, 2003, Journal of neurochemistry.

Chronic treatment with a novel γ‐secretase modulator, JNJ‐40418677, inhibits amyloid plaque formation in a mouse model of Alzheimer's disease

N. Ramsden, C. Hopf, M. Mercken, 2011, British journal of pharmacology.

Abeta localization in abnormal endosomes: association with earliest Abeta elevations in AD and Down syndrome.

J. Buxbaum, V. Haroutunian, P. Mehta, 2004, Neurobiology of aging.

Immunocytochemistry of tau phosphoserine 413 and tau protein kinase I in Alzheimer pathology

K. Imahori, M. Mercken, R. Nixon, 1996, Brain Research.

Comparison of size distribution and (Pro249-Ser258) epitope exposure in in vitro and in vivo derived Tau fibrils

M. Mercken, L. Schoofs, L. Temmerman, 2020, BMC molecular and cell biology.

Acute effect on the Aβ isoform pattern in CSF in response to γ-secretase modulator and inhibitor treatment in dogs.

K. Blennow, M. Mercken, H. Zetterberg, 2010, Journal of Alzheimer's disease : JAD.

Development of a specific ELISA for the quantitative study of amino-terminally truncated beta-amyloid peptides

T. Meert, M. Vandermeeren, M. Mercken, 2005, Journal of Neuroscience Methods.

Development of immunoprecipitation - two-dimensional liquid chromatography - mass spectrometry methodology as biomarker read-out to quantify phosphorylated tau in cerebrospinal fluid from Alzheimer disease patients.

M. Mercken, Farid Jahouh, L. Dillen, 2021, Journal of chromatography. A.

Characterization of Abeta11-40/42 peptide deposition in Alzheimer's disease and young Down's syndrome brains: implication of N-terminally truncated Abeta species in the pathogenesis of Alzheimer's disease.

J. Trojanowski, V. Lee, D. Mann, 2006, Acta neuropathologica.

Localization of Alzheimer-associated presenilin 1 in transfected COS-7 cells.

M. Mercken, A. Takashima, M. Sato, 1996, Biochemical and biophysical research communications.

Development and Characterization of Mouse-Specific Anti-Tau Monoclonal Antibodies: Relevance for Analysis of Murine Tau in Cerebrospinal Fluid.

M. Vandermeeren, M. Mercken, C. Delay, 2023, Journal of Alzheimer's disease : JAD.

Enhancement of therapeutic potential of a naturally occurring human antibody targeting a phosphorylated Ser422 containing epitope on pathological tau

S. Steinbacher, M. Mercken, J. Hoozemans, 2018, Acta neuropathologica communications.

A b peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer ' s disease

D. Westaway, P. Fraser, P. George-Hyslop, 2022 .

A common antigenic motif recognized by naturally occurring human VH5–51/VL4–1 anti-tau antibodies with distinct functionalities

Martin H. Koldijk, S. Steinbacher, I. Wilson, 2018, Acta neuropathologica communications.

Soluble amyloid precursor protein α and β in CSF in Alzheimer's disease

K. Blennow, L. Minthon, O. Hansson, 2013, Brain Research.

Design and synthesis of bicyclic heterocycles as potent γ-secretase modulators.

G. Macdonald, G. Tresadern, M. Mercken, 2013, Bioorganic & medicinal chemistry letters.

Mass spectrometric characterization of intact desferal-conjugated monoclonal antibodies for immuno-PET imaging.

M. Mercken, D. Pemberton, B. Van Broeck, 2018, Rapid communications in mass spectrometry : RCM.

Synthesis and Evaluation of a Zr-89-Labeled Monoclonal Antibody for Immuno-PET Imaging of Amyloid-β Deposition in the Brain

S. Dedeurwaerdere, M. Mercken, S. Stroobants, 2016, Molecular Imaging and Biology.

γ-Secretase Modulators: Can We Combine Potency with Safety?

M. Mercken, H. Gijsen, 2012, International journal of Alzheimer's disease.

A SINGLE ASCENDING DOSE STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF THE ANTI-PHOSPHO-TAU ANTIBODY JNJ-63733657 IN HEALTHY SUBJECTS

M. Mercken, T. Malia, W. Galpern, 2019, Alzheimer's & Dementia.

In Vivo Amyloid-β Imaging in the APPPS1–21 Transgenic Mouse Model with a 89Zr-Labeled Monoclonal Antibody

S. Dedeurwaerdere, M. Mercken, S. Stroobants, 2016, Front. Aging Neurosci..

Three distinct axonal transport rates for tau, tubulin, and other microtubule-associated proteins: evidence for dynamic interactions of tau with microtubules in vivo

M. Mercken, I. Fischer, R. Nixon, 1995, The Journal of neuroscience : the official journal of the Society for Neuroscience.

Normal brain development in PS1 hypomorphic mice with markedly reduced gamma-secretase cleavage of betaAPP.

R. Rozmahel, P. S. St George-Hyslop, D. Westaway, 2002, Neurobiology of aging.

Cerebrospinal fluid p-tau217 performs better than p-tau181 as a biomarker of Alzheimer’s disease

D. Airey, O. Hansson, M. Mercken, 2020, Nature Communications.

Comment on “ApoE-Directed Therapeutics Rapidly Clear β-Amyloid and Reverse Deficits in AD Mouse Models”

R. D'Hooge, B. de Strooper, I. Tesseur, 2013, Science.

Common antigenic motif recognized by human VH5-51/VL4-1 tau antibodies with distinct functionalities

Martin H. Koldijk, S. Steinbacher, I. Wilson, 2018, bioRxiv.

P2X currents in peritoneal macrophages of wild type and P2X4 -/- mice.

T. Meert, M. Mercken, D. Moechars, 2007, Immunology letters.

Enhancement of therapeutic potential of a naturally occurring human antibody targeting a phosphorylated Ser422 containing epitope on pathological tau

S. Steinbacher, M. Mercken, J. Hoozemans, 2018, Acta Neuropathologica Communications.

The functional γ-secretase inhibitor prevents production of amyloid β 1–34 in human and murine cell lines

M. Vandermeeren, M. Mercken, L. Dillen, 2001, Neuroscience Letters.

The functional gamma-secretase inhibitor prevents production of amyloid beta 1-34 in human and murine cell lines.